Drug Trial Radar · NCT00216398
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Last checked: Nov 20, 2026Latest source record: Aug 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jun 2004
Primary completion
Jun 22, 2006
Study completion Jun 22, 2006
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.
Conditions
- Acromegaly
Interventions
Lanreotide (Autogel formulation)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage of patients with GH control (<5.0 mU.L) and normalised IGF-1 at week 44 compared to the baseline (Week 0) visit.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Westmead Hospital
Westmead, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.